BVS vs. NVCR, LIVN, WRBY, ENOV, TNDM, TMDX, CNMD, LMAT, SLNO, and INMD
Should you be buying Bioventus stock or one of its competitors? The main competitors of Bioventus include NovoCure (NVCR), LivaNova (LIVN), Warby Parker (WRBY), Enovis (ENOV), Tandem Diabetes Care (TNDM), TransMedics Group (TMDX), CONMED (CNMD), LeMaitre Vascular (LMAT), Soleno Therapeutics (SLNO), and InMode (INMD). These companies are all part of the "medical equipment" industry.
Bioventus vs.
NovoCure (NASDAQ:NVCR) and Bioventus (NYSE:BVS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation, community ranking and risk.
NovoCure currently has a consensus target price of $32.67, indicating a potential upside of 24.82%. Bioventus has a consensus target price of $15.00, indicating a potential upside of 49.40%. Given Bioventus' higher possible upside, analysts plainly believe Bioventus is more favorable than NovoCure.
84.6% of NovoCure shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 6.3% of NovoCure shares are owned by company insiders. Comparatively, 32.9% of Bioventus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Bioventus has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.
In the previous week, NovoCure had 20 more articles in the media than Bioventus. MarketBeat recorded 23 mentions for NovoCure and 3 mentions for Bioventus. NovoCure's average media sentiment score of 0.67 beat Bioventus' score of -0.06 indicating that NovoCure is being referred to more favorably in the media.
NovoCure has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.
Bioventus has a net margin of -7.11% compared to NovoCure's net margin of -25.93%. Bioventus' return on equity of 15.61% beat NovoCure's return on equity.
NovoCure received 447 more outperform votes than Bioventus when rated by MarketBeat users. Likewise, 63.68% of users gave NovoCure an outperform vote while only 62.50% of users gave Bioventus an outperform vote.
Summary
Bioventus beats NovoCure on 10 of the 17 factors compared between the two stocks.
Get Bioventus News Delivered to You Automatically
Sign up to receive the latest news and ratings for BVS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bioventus Competitors List
Related Companies and Tools
This page (NYSE:BVS) was last updated on 1/21/2025 by MarketBeat.com Staff
Free BVS Stock Alerts